ONCOC4, INC.

BioNTech reports Q3 2024 revenues of €1.2 billion, net profit of €198.1 million, and diluted earnings per share of €0.81. The company launched variant-adapted COVID-19 vaccines and initiated Phase 2 trials for BNT327/PM8002 in small-cell lung cancer and triple-negative breast cancer. A Phase 2 trial for mRNA-based individualized cancer vaccine candidate autogene cevumeran is on track for high-risk muscle-invasive urothelial cancer. BioNTech ended Q3 with €17.8 billion in cash and cash equivalents plus security investments, expecting to be at the low end of its full-year 2024 revenue guidance range of €2.5-3.1 billion.

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update

Related Clinical Trials:

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

PM8002 in the Treatment of Patients With Advanced Solid Tumors

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

HARE-40: HPV Anti-CD40 RNA vaccinE

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)